SCHEMBL24484692

SCHEMBL24484692

N#Cc1ccnc(CC2(F)CCNCC2)c1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 5/20 0.37
SYK P43405 1/20 0.36
AURKB Q96GD4 1/20 0.36
INCENP Q9NQS7 1/20 0.36
NPY5R Q15761 6/20 0.36
KCNH2 Q12809 4/20 0.36
MAP3K12 Q12852 1/20 0.35
MAPKAPK2 P49137 1/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
MBOAT4 Q96T53 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
USP2 O75604 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26081245 0.87 LRRK2 (0.35) LRRK2NPY5RKCNH2MAP3K12MBOAT4
SCHEMBL26081076 0.78 USP2 (0.37) LRRK2KCNH2MAPKAPK2USP2MAOB
SCHEMBL24484602 0.77 ADRB1 (0.47) SYKKCNH2MAP3K12MAPKAPK2SLC6A4
SCHEMBL24484263 0.74 HRH1 (0.36) LRRK2SYKKCNH2
Hydrochloric Acid SCHEMBL25402688 0.73 SLC6A4 (0.43) USP2SLC6A2SLC6A4SLC6A3
SCHEMBL26081246 0.72 TSHR (0.41) NPY5RKCNH2MBOAT4CLK4USP2
SCHEMBL24484644 0.72 P2RX7 (0.37) KCNH2DRD2DRD3USP2SLC6A2
SCHEMBL26081206 0.72 USP2 (0.51) KCNH2MAPKAPK2USP2SLC6A2SLC6A4
SCHEMBL24484629 0.71 NPY5R (0.34) LRRK2NPY5RDRD2DRD3
SCHEMBL17168474 0.71 MBOAT4 (0.40) NPY5RKCNH2MBOAT4CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022115620-A1 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS SAGE THERAPEUTICS, INC. (US) 2022-06-02 WO disclosed